Format

Send to

Choose Destination
Int Immunopharmacol. 2004 Nov;4(12):1537-47.

Angiogenesis as an immunopharmacologic target in inflammation and cancer.

Author information

1
Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing 400038, PR of China. bianxiuwu@263.net

Erratum in

  • Int Immunopharmacol. 2005 Mar;5(3):627.

Abstract

Many pathological processes including wound healing, chronic inflammation and cancer require angiogenesis, i.e., the formation of new vasculature in the lesions. Accumulating evidence indicates that angiogenesis is crucial for both chronic inflammation and the growth of malignant tumors with the participation of diverse cytokines, chemokines and growth factors. It is nevertheless believed that differences exist in angiogenesis between cancer and chronic inflammatory diseases. The aim of this review is to outline the characteristics of angiogenesis in chronic inflammation and cancer. A better understanding of the angiogenic processes may facilitate the design of more effective therapies for chronic inflammation and cancer.

PMID:
15351323
DOI:
10.1016/j.intimp.2004.07.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center